RJA
TARS icon

Raymond James & Associates’s Tarsus Pharmaceuticals TARS Stock Holding History

Raymond James & Associates’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10,111
Closed -$180K – 3948
2023
Q3 		$180K Buy
+10,111
New +$179K ﹤0.01% 3489

Other funds holding TARS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Raymond James & Associates's TARS Position: Q4 2023 in Review

Raymond James & Associates sold out of Tarsus Pharmaceuticals (TARS) in Q4 2023, closing a stake of 10,111 shares — an estimated $180K sold.

Raymond James & Associates first reported a position in TARS in Q3 2023 and held it in 1 quarter. The position peaked at $180K in Q3 2023. 116 funds tracked by Wall St. Rank hold TARS as of Q4 2023.

  • Raymond James & Associates reported no remaining Tarsus Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Raymond James & Associates sold 10,111 Tarsus Pharmaceuticals shares in Q4 2023, an estimated $180K.
  • Raymond James & Associates first reported a position in Tarsus Pharmaceuticals in Q3 2023 and held it in 1 quarter.
  • Raymond James & Associates's Tarsus Pharmaceuticals position peaked at $180K in Q3 2023.
  • 116 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q4 2023.

Based on Raymond James & Associates's 13F filing for Q4 2023, filed 16 Jan 2024.